CoChat

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

Open access
Liebowitz, Michael, Lam, Raymond W., Lepola, Ulla, Datto, Catherine, Sweitzer, Dennis, Eriksson, Hans · 2010 · Depression and Anxiety
Cited by 86

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

PRIMARY OBJECTIVE: evaluate the efficacy (time to recurrence of depressive symptoms) of once daily extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy treatment to prevent relapse for major depressive disorder (MDD). METHODS: Time-to-event (maximum 52 weeks), double-blind, multicenter, randomized withdrawal, placebo-controlled study of quetiapine XR (50-300 mg/day) comprising four treatment phases: enrollment (up to 28 days), open-label run-in (4-8 weeks), open-label stabilization (12-18 weeks), and randomization (up to 52 weeks). Seven hundred and seventy-six patients stabilized on quetiapine XR were eligible for randomization (Montgomery-Åsberg Depression Rating Scale [MADRS] score ≤12 and Clinical Global Impression-Severity of Illness [CGI-S] score ≤3); 391 received quetiapine XR and 385 received placebo (same dose as last open-label visit). Primary endpoint: time to recurrence of depressive event from randomization. Secondary outcomes included changes from randomization in MADRS total, CGI-S, Pittsburgh Sleep Quality Index (PSQI) global, and Hamilton Anxiety Rating Scale (HAM-A) total scores. Adverse events were recorded throughout. RESULTS: Risk of recurrence of depressive event was significantly (P<.001) reduced by 66% (HR=.34; 95% CI: .25, .46) in patients randomized to continue with quetiapine XR versus patients randomized to switch to placebo. During the randomized phase, quetiapine XR maintained improvements in secondary outcomes (P<.001 for all): MADRS (0.15 versus 2.03), CGI-S (-0.03 versus 0.23); PSQI global (0.06 versus 1.35), and HAM-A total score (0.20 versus 1.58), respectively. The most common AEs (>10% any group) during the randomized period were headache and insomnia. CONCLUSIONS: Quetiapine XR maintenance therapy significantly reduced the risk of a depressive event in patients with MDD stabilized on quetiapine XR, with a safety and tolerability profile consistent with the known profile of quetiapine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.20740

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 34

  1. Shelton, 2004, Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?, J Clin Psychiatry, 65, 29
  2. Hansen, 2005, Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder, Ann Intern Med, 143, 415, 10.7326/0003-4819-143-6-200509200-00006 · DOI · Paper page
  3. Bauer, 2007, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care, World J Biol Psychiatry, 8, 67, 10.1080/15622970701227829 · DOI · Paper page
  4. Nemeroff, 2007, Prevalence and management of treatment-resistant depression, J Clin Psychiatry, 68, 17
  5. Trivedi, 2008, Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression, J Clin Psychiatry, 69, 246, 10.4088/JCP.v69n0211 · DOI · Paper page
  6. Schatzberg, 2007, Safety and tolerability of antidepressants: weighing the impact on treatment decisions, J Clin Psychiatry, 68, 26
  7. Weisler, 2008, Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post-hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies, J Clin Psychiatry, 69, 769, 10.4088/JCP.v69n0510 · DOI
  8. Young, 2008, A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I), Bipolar Disord, 10, 1
  9. McElroy, 2008, Double-blind, randomized, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II), Bipolar Disord, 10, 1
  10. Cutler, 2009, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study, J Clin Psychiatry, 70, 526, 10.4088/JCP.08m04592 · DOI · Paper page
  11. Bortnick, 2010, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study, J Affect Disord
  12. Weisler, 2009, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo controlled study, CNS Spectr, 14, 299, 10.1017/S1092852900020307 · DOI
  13. El-Khalili, 2010, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment-a multicentre, randomized, double-blind, placebo-controlled study, Int J Neuropsychopharmacol, 13, 917, 10.1017/S1461145710000015 · DOI · Paper page
  14. Jensen, 2008, N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity, Neuropsychopharmacology, 33, 2303, 10.1038/sj.npp.1301646 · DOI · Paper page
  15. Goldstein, 2008, Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel, Eur Psychiatry, 23, S202, 10.1016/j.eurpsy.2008.01.325 · DOI
  16. Nyberg, 2008, PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects, Eur Neuropsychopharmacol, 18, S270, 10.1016/S0924-977X(08)70352-3 · doi:10.1016/s0924-977x(08)70352-3
  17. Goldstein, 2007, Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors, Eur Neuropsychopharmacol, 17, S401, 10.1016/S0924-977X(07)70598-9 · doi:10.1016/s0924-977x(07)70598-9
  18. Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  19. Montgomery, 1979, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  20. National Institute of Mental Health, 1976, Manual for the ECDEU Assessment Battery, 217
  21. Hamilton, 1959, The assessment of anxiety states by rating, Br J Med Psychol, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  22. Endicott, 1993, Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure, Psychopharmacol Bull, 29, 321
  23. Buysse, 1989, The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research, Psychiatry Res, 28, 193, 10.1016/0165-1781(89)90047-4 · DOI · Paper page
  24. 1996, The Anxiety Disease
  25. Rosenbaum, 1998, Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial, Biol Psychiatry, 44, 77, 10.1016/S0006-3223(98)00126-7 · DOI · Paper page
  26. Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr Scand Suppl, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  27. Barnes, 1989, A rating scale for drug-induced akathisia, Br J Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
  28. Guy, 1976, ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ no ADM 766-338), 534
  29. Doogan, 1992, Sertraline in the prevention of depression, Br J Psychiatry, 160, 217, 10.1192/bjp.160.2.217 · DOI · Paper page
  30. Corya, 2003, Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study, J Clin Psychiatry, 64, 1349, 10.4088/JCP.v64n1111 · DOI
  31. Leo, 1996, Movement disorders associated with the serotonin selective reuptake inhibitors, J Clin Psychiatry, 57, 449, 10.4088/JCP.v57n1002 · DOI · Paper page
  32. Sajatovic, 2002, Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis, J Clin Psychiatry, 63, 1156, 10.4088/JCP.v63n1211 · DOI · Paper page
  33. Weiden, 2007, EPS profiles: the atypical antipsychotics: are not all the same, J Psychiatr Pract, 13, 13, 10.1097/00131746-200701000-00003 · DOI
  34. Miller, 2008, Extrapyramidal side-effects of antipsychotics in a randomised trial, Br J Psychiatry, 193, 279, 10.1192/bjp.bp.108.050088 · DOI · Paper page

Cited by

See all 86

Metadata

Authors
Liebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H.
Venue
Depression and Anxiety
Published
2010-08-23
Volume
27
Issue
10
Pages
964-976
ISSN
1091-4269 (ISSN-L)
OpenAlex
W2021696580
Cited by
86
References
7
FWCI
7.38
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1835 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1002/da.20740
The paper
Liebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010). Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depression and Anxiety. https://doi.org/10.1002/da.20740

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.